FIGURE 1.

Schematic representation of Notch receptor activation and avenues for therapeutic intervention. The pathway is activated by ligand binding to Notch receptor, followed by proteolytic cleavage fy proteases. This releases the Notch intracellular domain, which is then transferred to nucleus for biding with C protein binding factor 1/Suppressor of Hairless/Lag-1 allowing conversion of complex from repressor to activator of Notch genes. From inhibition perspective, γ-secretase inhibitors and monoclonal antibodies can inhibit Notch ligands and receptors (Yuan et al., 2015; Medina et al., 2020).